VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
HNGE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HNGEHinge Health, Inc.
$114.41$8.9B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. HNGE
  4. Financial Ratios

Hinge Health, Inc. (HNGE) Financial Ratios

Latest Ratios: P/E Ratio 58.8x · EV/EBITDA 55.6x · ROE -132.9%. (2023–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

HNGE Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023
Market Cap$8.9B$3.8B——
Enterprise Value$8.7B$3.6B——
P/E Ratio →58.82———
P/S Ratio11.056.46——
P/B Ratio24.6910.02——
P/FCF27.7822.23——
P/OCF51.6422.13——

P/E links to full P/E history page with 30-year chart

HNGE EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023
EV / Revenue—6.12——
EV / EBITDA55.55———
EV / EBIT————
EV / FCF—21.06——

HNGE Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023
Gross Margin79.8%79.8%77.0%66.3%
Operating Margin-92.9%-92.9%-8.2%-44.6%
Net Profit Margin-89.9%-89.9%-3.1%-36.9%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023
ROE-132.9%-132.9%-2.8%-25.3%
ROA-74.5%-74.5%-1.8%-17.4%
ROIC-268.2%-268.2%-14.3%-47.0%
ROCE-135.5%-135.5%-7.4%-29.8%

HNGE Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023
Debt / Equity0.020.020.030.04
Debt / EBITDA————
Net Debt / Equity—-0.53-0.70-0.51
Net Debt / EBITDA————
Debt / FCF—-1.17-6.41—
Interest Coverage————

Net cash position: cash ($208M) exceeds total debt ($8M)

HNGE Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023
Current Ratio1.471.472.342.88
Quick Ratio1.431.432.302.81
Cash Ratio1.001.001.872.30
Asset Turnover—0.790.580.47
Inventory Turnover7.587.588.267.41
Days Sales Outstanding—41.0239.7358.06

HNGE Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023
Dividend Yield————
Payout Ratio————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023
Earnings Yield1.7%———
FCF Yield3.6%4.5%——
Buyback Yield0.7%1.7%——
Total Shareholder Yield0.7%1.7%——
Shares Outstanding—$82M$78M$78M

Key Metrics

Growth RegimeExpanding
ProfitabilityModerate
Balance SheetHealthy
Cash FlowRobust
Top Statement Risk

Operating margin recently turned positive

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Multiples Price in Sustained Growth

HNGE trades at a trailing P/E of 62.57 and an EV/EBITDA of 59.18, with forward P/E compressing to 48.99, suggesting the market is capitalizing growth well ahead of current earnings power based on reported figures.

Compared with its own trailing history, the multiple remains elevated, and the compression from trailing to forward P/E implies analysts expect earnings to roughly double over the coming year. Relative to peers, where Teladoc carries a negative P/E and Omnicell trades at 37.01, HNGE is priced as a growth asset rather than a value holding. Investors should monitor whether margin expansion keeps pace, since the multiple leaves limited room for execution slippage.

Gross Margin Strength Masks Operating Gap

Gross margin expanded from 74.2% in 2024Q2 to 87.0% in 2026Q3, while operating margin reached 21.4%, according to reported quarterly figures, indicating improving unit economics but uneven conversion to operating profit.

The gap between gross margin and operating margin reflects a heavy fixed cost base in sales and R&D that has only recently been absorbed by scale. Net margin of 24.4% in 2026Q3 is flattered by non-operating items, as the 2025Q1 net margin of 98.0% against a much smaller operating result demonstrates. Operating margin is the more reliable gauge of earning power, and its sustained move above zero is the key signal to watch.

ROIC Recovery From Near-Zero Baseline

ROIC climbed from negative territory in 2025Q3 to 40.6% in 2026Q3, and ROE rose to 17.8%, based on reported quarterly ratios, suggesting returns are compounding off a depressed base.

The rapid improvement is driven largely by operating margin recovery rather than capital efficiency, since asset turnover of 0.28 remains low for a software-led model. The ROIC figure may be inflated by a thin invested capital base following the accumulated deficit. Investors should treat the trajectory as encouraging but early, pending confirmation over several more quarters.

Current Ratio Tightens as Cash Builds

The current ratio fell from 2.31 in 2025Q1 to 1.04 in 2026Q3 even as cash reached $211.6M, according to reported figures, indicating a thinner short-term buffer driven by growing current liabilities.

The decline appears tied to deferred revenue and working capital dynamics rather than weaker cash generation, which remained strong. A quick ratio of 1.01 still covers current obligations without relying on inventory, which is minimal for this model. Under severe stress, the position would depend on continued collection of receivables and renewal of enterprise contracts.

Minimal Debt Keeps Solvency Risk Low

Debt-to-equity of 0.11 and debt-to-EBITDA of 0.64 in 2026Q3, based on reported figures, indicate a lightly levered balance sheet with limited refinancing exposure.

Interest coverage is not meaningful given operating income only recently turned positive, so debt service capacity is better judged through cash generation than earnings. The absence of meaningful borrowings suggests covenant risk is low. The leverage profile would only become a concern if operating cash flow reversed sharply.

Deferred Revenue Flatters Cash Quality

Operating cash flow of $114.6M against $57.4M of net income in 2026Q3 appears strong, but according to recent SEC filings, stock-based compensation of $19.5M is added back, so part of the cash strength may reflect equity dilution.

The ratio of operating cash flow to net income is supported by large deferred revenue balances, which mean cash is collected ahead of service delivery and can reverse as contract timing shifts. Treating stock-based compensation as a real cost would lower the adjusted free cash flow margin materially below the reported 47.9%. Investors may wish to monitor deferred revenue growth against recognized revenue to judge whether cash conversion is durable.

Download Financial Ratios Data

Includes 30+ ratios · 3 years · Updated daily

Consensus & Technical Research Suite
Open HNGE Terminal

HNGE Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

HNGE — Frequently Asked Questions

Quick answers to the most common questions about buying HNGE stock.

What is Hinge Health, Inc.'s P/E ratio?

Hinge Health, Inc.'s current P/E ratio is 58.8x. This places it at the 50th percentile of its historical range.

What is Hinge Health, Inc.'s EV/EBITDA?

Hinge Health, Inc.'s current EV/EBITDA is 55.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.

What is Hinge Health, Inc.'s ROE?

Hinge Health, Inc.'s return on equity (ROE) is -132.9%. The historical average is -53.7%.

Is HNGE stock overvalued?

Based on historical data, Hinge Health, Inc. is trading at a P/E of 58.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Hinge Health, Inc.'s profit margins?

Hinge Health, Inc. has 79.8% gross margin and -92.9% operating margin.